ea0070aep997 | Thyroid | ECE2020
González Lázaro Paloma
, Contreras Pascual Cristina
, Montalbán Méndez Cristina
, Moreno Tirado Antonio
, Javier Gomez Alfonso Francisco
, del Val Zaballos Florentino
, Silva Fernández Julia
, Gomez Garcia Ines
Introduction: TKIs including anti-VEGF receptor activity have been approved for the treatment of patients with radioiodine resistant thyroid carcinomas. For lenvatinib arterial thromboembolic events are listed as adverse events of special interest. In the phase III study of SELECT trial, arterial thromboembolic events were reported in 3% of lenvatinib-treated patients and 1% in the placebo group. Most of the patients had predisposing factors. Only one myocardial infarct was re...